# LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

> **NCT02328105** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 11 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT02328105
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-06-15
- **Final completion:** 2019-12-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02328105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02328105, "LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02328105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*